Application of statins and PCSK9 inhibitors in patients with symptomatic intracranial atherosclerotic stenosis
10.3760/cma.j.issn.1673-4165.2025.06.010
- VernacularTitle:他汀类药物和PCSK9抑制剂在有症状颅内动脉粥样硬化性狭窄患者中的应用
- Author:
Yanming BAO
1
;
Jingfen ZHANG
;
Xia LI
;
Shaokai XU
Author Information
1. 内蒙古医科大学包头临床医学院，包头市中心医院神经内科，包头 014040
- Keywords:
Intracranial arteriosclerosis;
Stroke;
Ischemic attack, transient;
Hydroxymethylglutaryl-CoA reductase inhibitors;
PCSK9 inhibitors;
Cholesterol, LDL;
Secon
- From:
International Journal of Cerebrovascular Diseases
2025;33(6):462-467
- CountryChina
- Language:Chinese
-
Abstract:
Intracranial atherosclerotic stenosis (ICAS) is an important cause of ischemic stroke and transient ischemic attack. For patients with atherosclerotic stroke, it is recommended to use high-intensity statins, cholesterol absorption inhibitors and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for lipid-lowering treatment. This article reviews the current roles of statins and PCSK9 inhibitors in lowering lipids, reducing ischemic events, reducing the degree of vascular stenosis and the effect on atherosclerotic plaque in patients with symptomatic ICAS.
